Literature DB >> 12201863

Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology.

Kunio Okuda1, Yasuni Nakanuma, Masaru Miyazaki.   

Abstract

An attempt is made in this review to update the reader on recent developments and progress in the study of cholangiocarcinoma: a major primary carcinoma of the liver with a very poor prognosis. Knowledge of the cell biology and physiological functions of the cholangiocyte has recently so progressed that our understanding of cholangiocarcinogenetic mechanism is expected to follow. The first part of the review deals with semantic problems, temporal changes in the incidence of cholangiocarcinoma and geographic differences in epidemiology, etiologic factors (particularly opistorchiasis in Thailand and hepatolithiasis in the Far East), and discusses a recently disclosed role of hepatitis C virus infection (30% of cholangiocarcinoma patients have antibodies against hepatitis C virus in Japan).

Entities:  

Mesh:

Year:  2002        PMID: 12201863     DOI: 10.1046/j.1440-1746.2002.02781.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  51 in total

1.  Serum and biliary MMP-9 and TIMP-1 concentrations in the diagnosis of cholangiocarcinoma.

Authors:  Ali Tüzün İnce; Kemal Yıldız; Venkatanarayana Gangarapu; Yusuf Kayar; Birol Baysal; Oğuzhan Karatepe; Ahu Sarbay Kemik; Hakan Şentürk
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Small intestinal metastasis from intrahepatic cholangiocarcinoma: report of a case.

Authors:  Hironori Hayashi; Takashi Tani; Hidehiro Tajima; Yasuhiro Shoji; Shiro Terai; Ichiro Onishi; Hiroyuki Takamura; Hirohisa Kitagawa; Masato Kayahara; Tetsuo Ohta
Journal:  Surg Today       Date:  2011-05-28       Impact factor: 2.549

Review 3.  Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.

Authors:  Halim Charbel; Firas H Al-Kawas
Journal:  Curr Gastroenterol Rep       Date:  2011-04

Review 4.  Surgical treatment for intrahepatic cholangiocarcinoma.

Authors:  Takahiro Uenishi; Takatsugu Yamamoto; Shigekazu Takemura; Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2014-02-15

5.  International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.

Authors:  Jessica L Petrick; Megan Braunlin; Mathieu Laversanne; Patricia C Valery; Freddie Bray; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2016-06-28       Impact factor: 7.396

6.  Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China.

Authors:  Zongtang Sun; Taoyang Chen; Snorri S Thorgeirsson; Qimin Zhan; Jianguo Chen; Ju-Hyun Park; Peixin Lu; Chu Chieh Hsia; Nengjin Wang; Libin Xu; Lingling Lu; Fei Huang; Yuanrong Zhu; Jianhua Lu; Zhengping Ni; Qinan Zhang; Yuying Wu; Guoting Liu; Zhiyuan Wu; Chunfeng Qu; Mitchell H Gail
Journal:  Carcinogenesis       Date:  2013-01-14       Impact factor: 4.944

7.  Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Min Kyung Lim; Aesun Shin; Hyun-Joo Kong; Kyu-Won Jung; Young-Joo Won; Sohee Park; Sang-Jae Park; Sung-Tae Hong
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

8.  Methylsulfonylmethane suppresses hepatic tumor development through activation of apoptosis.

Authors:  Joo-Hyun Kim; Hye-Jun Shin; Hye-Lin Ha; Young-Ho Park; Tae-Ho Kwon; Mi-Ra Jung; Hyung-Bae Moon; Eun-Sang Cho; Hwa-Young Son; Dae-Yeul Yu
Journal:  World J Hepatol       Date:  2014-02-27

Review 9.  Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis.

Authors:  Zheng Wang; Yuan-Yuan Sheng; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

Review 10.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.